Y43: Primarily systemic agents
Y43.1: Antineoplastic antimetabolites
Antineoplastic antimetabolites refer to a class of medications used primarily in the treatment of cancer. These medications work by disrupting cell growth, particularly in rapidly multiplying cells like those found in various types of cancer. The interference with cellular growth and division, while targeting cancerous cells, can also affect healthy cells, leading to various side effects. Common side effects include fatigue, nausea, hair loss, and anemia, among others. Specific effects can depend on the particular antineoplastic antimetabolite medication in question and the type and stage of cancer being treated. Unfortunately, adverse events can arise from the use of antineoplastic antimetabolites. These potential risks, as coded by Y43.1, can be severe and have a profound effect on a patient's health, and include complications such as damage to certain organ systems or development of secondary cancers. All these factors are considered when deciding on the use of these medications as part of a comprehensive cancer treatment plan.
Patient Disclaimer
The information provided on this page is for general educational purposes only. It is not intended for self-diagnosis and does not replace professional medical advice. Always consult your doctor or a qualified healthcare provider with any questions or concerns about your health.
If you see an ICD diagnosis code (e.g., on a medical report), be aware that doctors may also include additional indicators to express diagnostic certainty. Only a healthcare professional can interpret these codes accurately in the context of your individual case.
For a complete understanding of your condition and what the diagnosis means for you, please speak directly with your doctor.